Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Cytisine in Healthy Smokers
NCT03509948Phase 1Completed
- Sponsor
- Achieve Life Sciences
- Start
- Apr 2018
- Primary completion
- Jun 2018
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cytisinicline in nicotine dependence (2 arms), sponsored by Achieve Life Sciences. Primary endpoints: Maximum Concentration, Area Under the Concentration Versus Time Curve Extrapolated to Infinity and 2 more. Started Apr 2018; status: completed.
02
Drugs
cytisinicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT03509948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03509948.